EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Bupivacaine-Meloxicam Extended-Release Solution Compared with a Standard Periarticular Injection in Primary Total Knee Arthroplasty

Harold I Salmons iD, Adam W Amundson iD, Christopher M Duncan iD, Dirk R Larson, Benjamin D Mallinger iD, Cory G Couch, Mark W Pagnano, Robert T Trousdale iD, Matthew P Abdel iD

Journal of Bone and Joint Surgery · 2025

DOI: 10.2106/jbjs.25.00086 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Harold I Salmons und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Postoperative Pain, Bupivacaine, Anesthetics, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The U.S. Food and Drug Administration has approved a bupivacaine and meloxicam extended-release (ER) intra-articular injection for pain during total knee arthroplasty (TKA). However, the real-world evidence with regard to analgesic efficacy of that medication has been limited. This randomized clinical trial investigated the efficacy of this new medication compared with our standard periarticular injection for postoperative analgesia after primary TKA.

Methods

Eligible patients undergoing primary, unilateral TKA for osteoarthritis at our academic center were enrolled. Patients were blinded and were randomized 1:1 to the bupivacaine-meloxicam ER (ZYNRELEF) injection group or the standard injection (ropivacaine, ketorolac, epinephrine) control group. A standardized, multimodal analgesic pathway was implemented. Numeric Rating Scale (NRS) pain scores and tallies of opioid consumption were collected. The primary outcome was the area under the curve (AUC) for NRS pain, adjusted for opioid consumption, over 72 hours. The minimal clinically important difference was considered to be 30%. Power analysis determined a minimum of 44 patients per group. The final groups included 53 patients in the experimental group and 48 patients in the control group.

Results

Similar postoperative analgesia was observed, with an AUC for the adjusted NRS pain score up to 72 hours of 331 in the experimental group and 373 in the control group (p = 0.09). The mean maximum NRS pain scores were similar and reflected good, but not complete, analgesia. Scores were 3 to 5 on the day of the surgery, 4 to 6 on postoperative day (POD) 1, 5 to 6 on POD 2, and 4 to 5 on POD 3 (p > 0.05). One patient in the experimental group and 2 patients in the control group had early postoperative complications, none of which was deemed to be related to the analgesic choice.

Conclusions

This randomized clinical trial demonstrated similar analgesia with a bupivacaine-meloxicam ER solution and a standard periarticular injection up to 72 hours after primary TKA. Cost, reimbursement, and convenience may ultimately prove to be more important than analgesic differences when choosing between these 2 effective options for managing postoperative pain. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, KneePostoperative PainBupivacaineAnesthetics, LocalMeloxicamAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleInjections, Intra-ArticularAgedMiddle AgedDelayed-Action PreparationsPain MeasurementTreatment OutcomeOsteoarthritis, KneeAnalgesics, Opioid

Substanzen

BupivacaineAnesthetics, LocalDelayed-Action PreparationsMeloxicamAnti-Inflammatory Agents, Non-SteroidalAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
  • Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

ORCID-Profile: Harold I Salmons, Adam W Amundson, Christopher M Duncan, Benjamin D Mallinger, Robert T Trousdale, Matthew P Abdel

Zitieren

APA

Salmons, H. I., Amundson, A. W., Duncan, C. M., Larson, D. R., Mallinger, B. D., Couch, C. G., Pagnano, M. W., Trousdale, R. T., & Abdel, M. P. (2025). Bupivacaine-Meloxicam Extended-Release Solution Compared with a Standard Periarticular Injection in Primary Total Knee Arthroplasty. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.25.00086

Vancouver

Salmons HI, Amundson AW, Duncan CM, Larson DR, Mallinger BD, Couch CG, et al. Bupivacaine-Meloxicam Extended-Release Solution Compared with a Standard Periarticular Injection in Primary Total Knee Arthroplasty. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.25.00086

BibTeX
@article{Salmons2025,
  author = {Salmons, Harold I and Amundson, Adam W and Duncan, Christopher M and Larson, Dirk R and Mallinger, Benjamin D and Couch, Cory G and Pagnano, Mark W and Trousdale, Robert T and Abdel, Matthew P},
  title = {Bupivacaine-Meloxicam Extended-Release Solution Compared with a Standard Periarticular Injection in Primary Total Knee Arthroplasty},
  journal = {Journal of Bone and Joint Surgery},
  year = {2025},
  doi = {10.2106/jbjs.25.00086}
}
Kostenlos starten →